Cervical Cancer - Pipeline Review, H2 2016

 


Get this Report



PayPal Verified Vendor

Rating

4.9 Star Rating for report Cervical Cancer - Pipeline Review, H2 2016
4.9 / 5 stars rating
Pages: 472
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2016, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8870IDBColorectal Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-11-23 

Report: Cervical Cancer - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Cervical Cancer Overview 12
Therapeutics Development 13
Pipeline Products for Cervical Cancer - Overview 13
Pipeline Products for Cervical Cancer - Comparative Analysis 14
Cervical Cancer - Therapeutics under Development by Companies 15
Cervical Cancer - Therapeutics under Investigation by Universities/Institutes 21
Cervical Cancer - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Cervical Cancer - Products under Development by Companies 26
Cervical Cancer - Products under Investigation by Universities/Institutes 33
Cervical Cancer - Companies Involved in Therapeutics Development 34
Abion Inc 34
Admedus Ltd 35
Advaxis Inc 36
Advenchen Laboratories LLC 37
Antigen Express Inc 38
Arbor Vita Corp 39
ArQule Inc 40
AstraZeneca Plc 41
AVEO Pharmaceuticals Inc 42
Azaya Therapeutics Inc 43
Bioleaders Corporation 44
Biomics Biotechnologies Co Ltd 45
Blirt SA 46
Boehringer Ingelheim GmbH 47
Bristol-Myers Squibb Company 48
Cancer Research Technology Ltd 49
Cell Medica Ltd 50
Cellceutix Corp 51
Coherus BioSciences Inc 52
Critical Outcome Technologies Inc 53
CZ BioMed Corp 54
DelMar Pharmaceuticals, Inc. 55
Dr. Reddy's Laboratories Ltd 56
EirGenix Inc. 57
Eisai Co Ltd 58
Etubics Corp 59
Eureka Therapeutics Inc 60
EyeGene Inc 61
F. Hoffmann-La Roche Ltd 62
Formune SL 63
GamaMabs Pharma SA 64
Gene Techno Science Co Ltd 65
Genexine Inc 66
Genmab A/S 67
Genor BioPharma Co Ltd 68
Genticel S.A. 69
GlaxoSmithKline Plc 70
Immune Therapeutics, Inc. 71
Immunovaccine Inc 72
INSYS Therapeutics Inc 73
ISA Pharmaceuticals BV 74
Johnson & Johnson 75
Karyopharm Therapeutics Inc 76
Kite Pharma Inc 77
LondonPharma Ltd 78
Mabion SA 79
Merck & Co Inc 80
Mycenax Biotech Inc 81
Nanotherapeutics Inc 82
Nektar Therapeutics 83
Oncobiologics Inc 84
Ono Pharmaceutical Co Ltd 85
Oryx GmbH & Co KG 86
PDS Biotechnology Corp 87
Pfizer Inc 88
Psicofarma SA de CV 89
Rexahn Pharmaceuticals Inc 90
Richter Gedeon Nyrt 91
Samyang Holdings Corp 92
Sanofi 93
Savoy Pharmaceuticals, Inc. 94
Seattle Genetics Inc 95
Selecta Biosciences Inc 96
Shantha Biotechnics Ltd 97
Sirnaomics Inc 98
Sun Pharma Advanced Research Company Ltd 99
Taiho Pharmaceutical Co Ltd 100
Tessa Therapeutics Pte Ltd 101
Theravectys SA 102
THEVAX Genetics Vaccine USA Inc 103
Tomegavax Inc 104
UbiVac LLC 105
VLPbio 106
Zeria Pharmaceutical Co Ltd 107
Zydus Cadila Healthcare Ltd 108
Cervical Cancer - Therapeutics Assessment 109
Assessment by Monotherapy Products 109
Assessment by Combination Products 110
Assessment by Target 111
Assessment by Mechanism of Action 116
Assessment by Route of Administration 121
Assessment by Molecule Type 123
Drug Profiles 125
(hydralazine + valproate magnesium) - Drug Profile 125
ABN-301 - Drug Profile 126
AEH-10p - Drug Profile 127
AL-3818 - Drug Profile 128
Ancer - Drug Profile 130
Antisense RNAi Oligonucleotide for Cervical Cancer - Drug Profile 131
Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile 132
ARQ-092 - Drug Profile 133
artemether - Drug Profile 136
atezolizumab - Drug Profile 138
AV-203 - Drug Profile 152
AVC-7 - Drug Profile 155
axalimogene filolisbac - Drug Profile 156
AZD-5363 - Drug Profile 173
bevacizumab biosimilar - Drug Profile 176
bevacizumab biosimilar - Drug Profile 178
bevacizumab biosimilar - Drug Profile 179
bevacizumab biosimilar - Drug Profile 180
bevacizumab biosimilar - Drug Profile 181
bevacizumab biosimilar - Drug Profile 182
bevacizumab biosimilar - Drug Profile 183
bevacizumab biosimilar - Drug Profile 184
bevacizumab biosimilar - Drug Profile 185
bevacizumab biosimilar - Drug Profile 186
bevacizumab biosimilar - Drug Profile 187
BLR-111 - Drug Profile 188
BLSILSB-710c - Drug Profile 189
BMS-986016 - Drug Profile 190
BVAC-C - Drug Profile 192
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 193
Cellular Immunotherapy for Oncology - Drug Profile 194
Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 195
Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 197
CerviVax - Drug Profile 199
Cervlysis - Drug Profile 200
CIGB-300 - Drug Profile 201
CMD-004 - Drug Profile 203
COTI-2 - Drug Profile 204
crocetin - Drug Profile 212
dianhydrogalactitol - Drug Profile 213
docetaxel - Drug Profile 225
DPXE-7 - Drug Profile 227
E-7046 - Drug Profile 228
EDA-HPVE7 - Drug Profile 229
EDOB-278 - Drug Profile 230
EF-022 - Drug Profile 231
EG-HPV - Drug Profile 232
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 233
ET-1502 - Drug Profile 234
ETBX-041 - Drug Profile 235
etirinotecan pegol - Drug Profile 236
GM-102 - Drug Profile 242
GSK-2256098 - Drug Profile 244
GSK-2849330 - Drug Profile 246
GTL-001 - Drug Profile 247
GTL-002 - Drug Profile 250
GX-I7 - Drug Profile 251
HPViNT - Drug Profile 252
human papillomavirus vaccine - Drug Profile 253
human papillomavirus vaccine - Drug Profile 254
human papillomavirus vaccine - Drug Profile 255
human papillomavirus vaccine - Drug Profile 256
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 257
ISA-101 - Drug Profile 258
JNJ-61610588 - Drug Profile 261
Kevetrin - Drug Profile 262
KITE-439 - Drug Profile 273
LN-145 - Drug Profile 274
Lovaxin S - Drug Profile 276
Monoclonal Antibody Conjugate to Target CD40 for Cervical, Head And Neck Cancer - Drug Profile 277
naltrexone hydrochloride - Drug Profile 278
nimotuzumab - Drug Profile 281
nintedanib - Drug Profile 285
NIT-02 - Drug Profile 295
nivolumab - Drug Profile 296
NP-001 - Drug Profile 330
NTO-1151 - Drug Profile 331
Oncoprev - Drug Profile 333
OTAC-DCtag - Drug Profile 334
paclitaxel - Drug Profile 335
paclitaxel - Drug Profile 337
paclitaxel albumin free - Drug Profile 341
PDS-0101 - Drug Profile 342
pembrolizumab - Drug Profile 344
PF-04518600 - Drug Profile 382
phosphoethanolamine - Drug Profile 384
RA-190 - Drug Profile 385
Recombinant Protein to Inhibit NFKB for Cervical Cancer and Breast Cancer - Drug Profile 386
RG-7876 - Drug Profile 387
RX-3117 - Drug Profile 388
S-009131 - Drug Profile 393
SAR-408701 - Drug Profile 394
SEL-701 - Drug Profile 395
selinexor - Drug Profile 396
SGN-LIV1A - Drug Profile 415
sirolimus albumin-bound - Drug Profile 417
Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology - Drug Profile 419
STP-900 - Drug Profile 420
Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile 421
Synthetic Peptides to Inhibit Bcl-x and MCL-1 for Oncology - Drug Profile 422
TA-CIN - Drug Profile 423
TAS-114 - Drug Profile 424
Tenacinol - Drug Profile 425
tisotumab vedotin - Drug Profile 426
TT-12 - Drug Profile 428
TVGV-1 - Drug Profile 429
utomilumab - Drug Profile 430
Vaccine for HPV Associated Cancers - Drug Profile 432
Vaccine for HPV Associated Cervical Cancer - Drug Profile 433
Vaccine for HPV Associated Cervical Cancer - Drug Profile 434
Vaccine for HPV Associated Cervical Cancer - Drug Profile 435
Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile 436
Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer - Drug Profile 437
Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile 438
Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer - Drug Profile 439
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 440
Vicoryx - Drug Profile 441
Vvax-001 - Drug Profile 442
Cervical Cancer - Dormant Projects 443
Cervical Cancer - Discontinued Products 450
Cervical Cancer - Product Development Milestones 451
Featured News & Press Releases 451
Appendix 463
Methodology 463
Coverage 463
Secondary Research 463
Primary Research 463
Expert Panel Validation 463
Contact Us 463
Disclaimer 46
 

List of Tables

List of Tables
Number of Products under Development for Cervical Cancer, H2 2016 21
Number of Products under Development for Cervical Cancer - Comparative Analysis, H2 2016 22
Number of Products under Development by Companies, H2 2016 23
Number of Products under Development by Companies, H2 2016 (Contd..1) 24
Number of Products under Development by Companies, H2 2016 (Contd..2) 25
Number of Products under Development by Companies, H2 2016 (Contd..3) 26
Number of Products under Development by Companies, H2 2016 (Contd..4) 27
Number of Products under Development by Companies, H2 2016 (Contd..5) 28
Number of Products under Investigation by Universities/Institutes, H2 2016 29
Comparative Analysis by Late Stage Development, H2 2016 30
Comparative Analysis by Clinical Stage Development, H2 2016 31
Comparative Analysis by Early Stage Development, H2 2016 32
Comparative Analysis by Unknown Stage Development, H2 2016 33
Products under Development by Companies, H2 2016 34
Products under Development by Companies, H2 2016 (Contd..1) 35
Products under Development by Companies, H2 2016 (Contd..2) 36
Products under Development by Companies, H2 2016 (Contd..3) 37
Products under Development by Companies, H2 2016 (Contd..4) 38
Products under Development by Companies, H2 2016 (Contd..5) 39
Products under Development by Companies, H2 2016 (Contd..6) 40
Products under Investigation by Universities/Institutes, H2 2016 41
Cervical Cancer - Pipeline by Abion Inc, H2 2016 42
Cervical Cancer - Pipeline by Admedus Ltd, H2 2016 43
Cervical Cancer - Pipeline by Advaxis Inc, H2 2016 44
Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 45
Cervical Cancer - Pipeline by Antigen Express Inc, H2 2016 46
Cervical Cancer - Pipeline by Arbor Vita Corp, H2 2016 47
Cervical Cancer - Pipeline by ArQule Inc, H2 2016 48
Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2016 49
Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 50
Cervical Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 51
Cervical Cancer - Pipeline by Bioleaders Corporation, H2 2016 52
Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016 53
Cervical Cancer - Pipeline by Blirt SA, H2 2016 54
Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 55
Cervical Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 56
Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H2 2016 57
Cervical Cancer - Pipeline by Cell Medica Ltd, H2 2016 58
Cervical Cancer - Pipeline by Cellceutix Corp, H2 2016 59
Cervical Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 60
Cervical Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 61
Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2016 62
Cervical Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H2 2016 63
Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 64
Cervical Cancer - Pipeline by EirGenix Inc., H2 2016 65
Cervical Cancer - Pipeline by Eisai Co Ltd, H2 2016 66
Cervical Cancer - Pipeline by Etubics Corp, H2 2016 67
Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016 68
Cervical Cancer - Pipeline by EyeGene Inc, H2 2016 69
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 70
Cervical Cancer - Pipeline by Formune SL, H2 2016 71
Cervical Cancer - Pipeline by GamaMabs Pharma SA, H2 2016 72
Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 73
Cervical Cancer - Pipeline by Genexine Inc, H2 2016 74
Cervical Cancer - Pipeline by Genmab A/S, H2 2016 75
Cervical Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 76
Cervical Cancer - Pipeline by Genticel S.A., H2 2016 77
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 78
Cervical Cancer - Pipeline by Immune Therapeutics, Inc., H2 2016 79
Cervical Cancer - Pipeline by Immunovaccine Inc, H2 2016 80
Cervical Cancer - Pipeline by INSYS Therapeutics Inc, H2 2016 81
Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2016 82
Cervical Cancer - Pipeline by Johnson & Johnson, H2 2016 83
Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 84
Cervical Cancer - Pipeline by Kite Pharma Inc, H2 2016 85
Cervical Cancer - Pipeline by LondonPharma Ltd, H2 2016 86
Cervical Cancer - Pipeline by Mabion SA, H2 2016 87
Cervical Cancer - Pipeline by Merck & Co Inc, H2 2016 88
Cervical Cancer - Pipeline by Mycenax Biotech Inc, H2 2016 89
Cervical Cancer - Pipeline by Nanotherapeutics Inc, H2 2016 90
Cervical Cancer - Pipeline by Nektar Therapeutics, H2 2016 91
Cervical Cancer - Pipeline by Oncobiologics Inc, H2 2016 92
Cervical Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 93
Cervical Cancer - Pipeline by Oryx GmbH & Co KG, H2 2016 94
Cervical Cancer - Pipeline by PDS Biotechnology Corp, H2 2016 95
Cervical Cancer - Pipeline by Pfizer Inc, H2 2016 96
Cervical Cancer - Pipeline by Psicofarma SA de CV, H2 2016 97
Cervical Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 98
Cervical Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016 99
Cervical Cancer - Pipeline by Samyang Holdings Corp, H2 2016 100
Cervical Cancer - Pipeline by Sanofi, H2 2016 101
Cervical Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 102
Cervical Cancer - Pipeline by Seattle Genetics Inc, H2 2016 103
Cervical Cancer - Pipeline by Selecta Biosciences Inc, H2 2016 104
Cervical Cancer - Pipeline by Shantha Biotechnics Ltd, H2 2016 105
Cervical Cancer - Pipeline by Sirnaomics Inc, H2 2016 106
Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 107
Cervical Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 108
Cervical Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 109
Cervical Cancer - Pipeline by Theravectys SA, H2 2016 110
Cervical Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016 111
Cervical Cancer - Pipeline by Tomegavax Inc, H2 2016 112
Cervical Cancer - Pipeline by UbiVac LLC, H2 2016 113
Cervical Cancer - Pipeline by VLPbio, H2 2016 114
Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2016 115
Cervical Cancer - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 116
Assessment by Monotherapy Products, H2 2016 117
Assessment by Combination Products, H2 2016 118
Number of Products by Stage and Target, H2 2016 120
Number of Products by Stage and Mechanism of Action, H2 2016 125
Number of Products by Stage and Route of Administration, H2 2016 130
Number of Products by Stage and Molecule Type, H2 2016 132
Cervical Cancer - Dormant Projects, H2 2016 451
Cervical Cancer - Dormant Projects (Contd..1), H2 2016 452
Cervical Cancer - Dormant Projects (Contd..2), H2 2016 453
Cervical Cancer - Dormant Projects (Contd..3), H2 2016 454
Cervical Cancer - Dormant Projects (Contd..4), H2 2016 455
Cervical Cancer - Dormant Projects (Contd..5), H2 2016 456
Cervical Cancer - Dormant Projects (Contd..6), H2 2016 457
Cervical Cancer - Discontinued Products, H2 2016 45
 

List of Figures

List of Figures
Number of Products under Development for Cervical Cancer, H2 2016 21
Number of Products under Development for Cervical Cancer - Comparative Analysis, H2 2016 22
Number of Products under Development by Companies, H2 2016 23
Number of Products under Investigation by Universities/Institutes, H2 2016 29
Comparative Analysis by Clinical Stage Development, H2 2016 31
Comparative Analysis by Early Stage Products, H2 2016 32
Assessment by Monotherapy Products, H2 2016 117
Number of Products by Top 10 Targets, H2 2016 119
Number of Products by Stage and Top 10 Targets, H2 2016 119
Number of Products by Top 10 Mechanism of Actions, H2 2016 124
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 124
Number of Products by Top 10 Routes of Administration, H2 2016 129
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 129
Number of Products by Top 10 Molecule Types, H2 2016 131
Number of Products by Stage and Top 10 Molecule Types, H2 2016 131
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 20, 29, 1, 39, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 1, 9 and 5 molecules, respectively.Cervical Cancer.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Oncology 
Pages: 472 

Companies Featured

Abion Inc Admedus Ltd Advaxis Inc Advenchen Laboratories LLC Antigen Express Inc Arbor Vita Corp ArQule Inc AstraZeneca Plc AVEO Pharmaceuticals Inc Azaya Therapeutics Inc Bioleaders Corporation Biomics Biotechnologies Co Ltd Blirt SA Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Cancer Research Technology Ltd Cell Medica Ltd Cellceutix Corp Coherus BioSciences Inc Critical Outcome Technologies Inc CZ BioMed Corp DelMar Pharmaceuticals, Inc. Dr. Reddy's Laboratories Ltd EirGenix Inc. Eisai Co Ltd Etubics Corp Eureka Therapeutics Inc EyeGene Inc F. Hoffmann-La Roche Ltd Formune SL GamaMabs Pharma SA Gene Techno Science Co Ltd Genexine Inc Genmab A/S Genor BioPharma Co Ltd Genticel S.A. GlaxoSmithKline Plc Immune Therapeutics, Inc. Immunovaccine Inc INSYS Therapeutics Inc ISA Pharmaceuticals BV Johnson & Johnson Karyopharm Therapeutics Inc Kite Pharma Inc LondonPharma Ltd Mabion SA Merck & Co Inc Mycenax Biotech Inc Nanotherapeutics Inc Nektar Therapeutics Oncobiologics Inc Ono Pharmaceutical Co Ltd Oryx GmbH & Co KG PDS Biotechnology Corp Pfizer Inc Psicofarma SA de CV Rexahn Pharmaceuticals Inc Richter Gedeon Nyrt Samyang Holdings Corp Sanofi Savoy Pharmaceuticals, Inc. Seattle Genetics Inc Selecta Biosciences Inc Shantha Biotechnics Ltd Sirnaomics Inc Sun Pharma Advanced Research Company Ltd Taiho Pharmaceutical Co Ltd Tessa Therapeutics Pte Ltd Theravectys SA THEVAX Genetics Vaccine USA Inc Tomegavax Inc UbiVac LLC VLPbio Zeria Pharmaceutical Co Ltd Zydus Cadila Healthcare Ltd

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8870IDBColorectal Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Cervical Cancer - Pipeline Review, H2 2016

Report 05IB-GMDHC8700IDB has a rating of 94.7 percent
Figure of merit assessment for report 05IB-GMDHC8700IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7174

Taxonomy Location

The taxonomy on the left shows the ancestors of the Oncology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Oncology

Oncology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Cervical Cancer - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8700IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [5.05800s]

--